Advance Search
ZOU Jinchan, LIU Xiaomin. Research progress on the protective effect of sodium-glucose cotransporter 2 inhibitor on kidney in patients with type 2 diabetes mellitus[J]. Journal of Clinical Medicine in Practice, 2021, 25(23): 129-132. DOI: 10.7619/jcmp.20212879
Citation: ZOU Jinchan, LIU Xiaomin. Research progress on the protective effect of sodium-glucose cotransporter 2 inhibitor on kidney in patients with type 2 diabetes mellitus[J]. Journal of Clinical Medicine in Practice, 2021, 25(23): 129-132. DOI: 10.7619/jcmp.20212879
shu

Research progress on the protective effect of sodium-glucose cotransporter 2 inhibitor on kidney in patients with type 2 diabetes mellitus

  • Department of Endocrinology,the First Affiliated Hospital of Harbin Medical University,Harbin,Heilongjiang,150001

More Information
  • Received Date: July 17, 2021
  • Available Online: December 20, 2021
    Graphical Abstract
    • Abstract

  • Sodium-glucose cotransporter 2 inhibitor is a new type of non-insulin-dependent oral hypoglycemic drug,which can reduce the reabsorption of glucose in the original urine,increase the excretion of urinary glucose and reduce blood sugar by inhibiting the activity of sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule.SGLT2i can also reduce blood pressure,arterial stiffness and blood uric acid,regulate renal hemodynamics,inhibit renin-angiotensin system (RAS) and sympathetic nervous system (SNS),reduce inflammation as well as oxidative stress and improve kidney hypoxia,thereby playing the role of kidney protection.In this review,the role of SGLT2 in the regulation of renal glucose metabolism and the research progress and corresponding mechanism of SGLT2i on renal protection were reviewed.

    • FullText(HTML)
    • References (28)
  • [1]
    CHERNEY D Z,ODUTAYO A,ARONSON R, et al.Sodium glucose cotransporter-2 inhibition and cardiorenal protection: JACC review topic of the week[J].J Am Coll Cardiol,2019,74(20): 2511-2524. doi: 10.1016/j.jacc.2019.09.022
    [2]
    FUJITA Y,INAGAKI N.Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action[J].J Diabetes Investig,2014,5(3): 265-275. doi: 10.1111/jdi.12214
    [3]
    WILDING J P.The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors[J].Metabolism,2014,63(10): 1228-1237. doi: 10.1016/j.metabol.2014.06.018
    [4]
    李航.肾脏在血糖调节中的作用[J].中国糖尿病杂志,2016,24(2): 184-186. doi: 10.3969/j.issn.1006-6187.2016.02.024
    [5]
    NI L,YUAN C,CHEN G, et al.SGLT2i: beyond the glucose-lowering effect[J].Cardiovasc Diabetol,2020,19(1): 98. doi: 10.1186/s12933-020-01071-y
    [6]
    李克柔,安赤颖,刘晓民.钠-葡萄糖共转运蛋白2抑制剂与酮症酸中毒: 关注降糖药的利与弊[J].中华糖尿病杂志,2019,11(4): 230-233. doi: 10.3760/cma.j.issn.1674-5809.2019.04.002
    [7]
    CASTAÑEDA A M,DUTRA-RUFATO A,JUAREZ M J, et al.Sodium-glucose cotransporter 2 inhibitors (SGLT2i): renal implications[J].Int Urol Nephrol,2021,53(2): 291-299. doi: 10.1007/s11255-020-02585-w
    [8]
    SALEEM F.Dapagliflozin: cardiovascular safety and benefits in type 2 diabetes mellitus[J].Cureus,2017,9(10): e1751.
    [9]
    HEERSPINK H J L,STEFÁNSSON B V,CORREA-ROTTER R, et al.Dapagliflozin in patients with chronic kidney disease[J].N Engl J Med,2020,383(15): 1436-1446. doi: 10.1056/NEJMoa2024816
    [10]
    PERKOVIC V,JARDINE M J,NEAL B, et al.Canagliflozin and renal outcomes in type 2 diabetes and nephropathy[J].N Engl J Med,2019,380(24): 2295-2306. doi: 10.1056/NEJMoa1811744
    [11]
    WILLIAMS D M,NAWAZ A,EVANS M.Renal outcomes in type 2 diabetes: a review of cardiovascular and renal outcome trials[J].Diabetes Ther,2020,11(2): 369-386. doi: 10.1007/s13300-019-00747-3
    [12]
    中华医学会肾脏病学分会专家组.糖尿病肾脏疾病临床诊疗中国指南[J].中华肾脏病杂志,2021,37(3): 255-304. doi: 10.3760/cma.j.cn441217-20201125-00041
    [13]
    中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版)[J].国际内分泌代谢杂志,2021,41(5): 482-548. doi: 10.3760/cma.j.cn121383-20210825-08063
    [14]
    SANIDAS E A,PAPADOPOULOS D P,HATZIAGELAKI E, et al.Sodium glucose cotransporter 2 (SGLT2) inhibitors across the spectrum of hypertension[J].Am J Hypertens,2020,33(3): 207-213.
    [15]
    SCHEEN A J.Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure[J].Curr Cardiol Rep,2019,21(8): 70. doi: 10.1007/s11886-019-1165-1
    [16]
    BAILEY C J.Uric acid and the cardio-renal effects of SGLT2 inhibitors[J].Diabetes Obes Metab,2019,21(6): 1291-1298. doi: 10.1111/dom.13670
    [17]
    SCHEEN A J.Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus[J].Nat Rev Endocrinol,2020,16(10): 556-577. doi: 10.1038/s41574-020-0392-2
    [18]
    TONNEIJCK L,MUSKIET M H,SMITS M M, et al.Glomerular hyperfiltration in diabetes: mechanisms,clinical significance,and treatment[J].J Am Soc Nephrol,2017,28(4): 1023-1039. doi: 10.1681/ASN.2016060666
    [19]
    BARUTTA F,BERNARDI S,GARGIULO G, et al.SGLT2 inhibition to address the unmet needs in diabetic nephropathy[J].Diabetes Metab Res Rev,2019,35(7): e3171. http://www.onacademic.com/detail/journal_1000042268662699_ddeb.html
    [20]
    THOMAS M C,CHERNEY D Z I.The actions of SGLT2 inhibitors on metabolism,renal function and blood pressure[J].Diabetologia,2018,61(10): 2098-2107. doi: 10.1007/s00125-018-4669-0
    [21]
    HERAT L Y,MAGNO A L,RUDNICKA C, et al.SGLT2 inhibitor-induced sympathoinhibition: a novel mechanism for cardiorenal protection[J].JACC Basic Transl Sci,2020,5(2): 169-179. doi: 10.1016/j.jacbts.2019.11.007
    [22]
    KLUGER A Y,TECSON K M,LEE A Y, et al.Class effects of SGLT2 inhibitors on cardiorenal outcomes[J].Cardiovasc Diabetol,2019,18(1): 99. doi: 10.1186/s12933-019-0903-4
    [23]
    HEERSPINK H J L,PERCO P,MULDER S, et al.Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease[J].Diabetologia,2019,62(7): 1154-1166. doi: 10.1007/s00125-019-4859-4
    [24]
    TSAI S F,TARNG D C.Anemia in patients of diabetic kidney disease[J].J Chin Med Assoc,2019,82(10): 752-755. doi: 10.1097/JCMA.0000000000000175
    [25]
    HEERSPINK H J L,PERKINS B A,FITCHETT D H, et al.Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects,potential mechanisms,and clinical applications[J].Circulation,2016,134(10): 752-772. doi: 10.1161/CIRCULATIONAHA.116.021887
    [26]
    TENTOLOURIS A,VLACHAKIS P,TZERAVINI E, et al.SGLT2 inhibitors: a review of their antidiabetic and cardioprotective effects[J].Int J Environ Res Public Heal,2019,16(16): 2965. doi: 10.3390/ijerph16162965
    [27]
    PACKER M.Mechanisms leading to differential hypoxia-inducible factor signaling in the diabetic kidney: modulation by SGLT2 inhibitors and hypoxia mimetics[J].Am J Kidney Dis,2021,77(2): 280-286. doi: 10.1053/j.ajkd.2020.04.016
    [28]
    BESSHO R,TAKIYAMA Y,TAKIYAMA T, et al.Hypoxia-inducible factor-1α is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy[J].Sci Rep,2019,9(1): 1-12.
    • Related Articles

  • Related Articles

    [1]CHEN Dandan, LUO Junhui, ZHANG Haitao, XIA Cui. Clinical effect of Mudan Granules combined with pentoxifylline in treatment of type 2 diabetes mellitus combined with early renal disease[J]. Journal of Clinical Medicine in Practice, 2024, 28(24): 116-120. DOI: 10.7619/jcmp.20243133
    [2]HU Xiujuan, HUI Cancan, WANG Shuqian, YIN Xiaorong, CUI Mengjie, HUANG Qinyi, YIN Yangliu, ZHANG Ya, SUN Yan. Prediction value of plasma arteriosclerosis index and insulin resistance index in combination in decreased estimated glomerular filtration rate in patients with type 2 diabetes mellitus[J]. Journal of Clinical Medicine in Practice, 2023, 27(20): 29-32. DOI: 10.7619/jcmp.20232415
    [3]GAO Luyang, HUANG Zhihua, LUO Qin, ZHAO Zhihui, ZHAO Qing, LIU Zhihong. Research advances of sodium-glucose cotransporter 2 inhibitors for the treatment of obstructive sleep apnea[J]. Journal of Clinical Medicine in Practice, 2023, 27(7): 133-137. DOI: 10.7619/jcmp.20230293
    [4]LI Mengfei, DU Xuanyi. Research progress of sodium-dependent glucose transporter 2 inhibitor in renal benefit[J]. Journal of Clinical Medicine in Practice, 2021, 25(14): 123-127. DOI: 10.7619/jcmp.20211379
    [5]ZHOU Xinglu, LU Jiancan, MENG Ying, ZHU Hongling. Effects of dapagliflozin on glucolipid metabolism and levels of renal injury markers in patients with type 2 diabetes mellitus[J]. Journal of Clinical Medicine in Practice, 2021, 25(5): 74-78. DOI: 10.7619/jcmp.20201394
    [6]LIU Jinyong, LI Ziyue, WANG Xinwen. Efficacy and safety of empagliflozin combined with metformin in treating patients with type 2 diabetes mellitus: a Meta-analysis[J]. Journal of Clinical Medicine in Practice, 2019, 23(16): 70-75. DOI: 10.7619/jcmp.201916019
    [7]MA Yanhua, WANG Haidong. Self-management behavior of patients with type 2 diabetes mellitus and its effect on blood glucose control[J]. Journal of Clinical Medicine in Practice, 2017, (6): 52-54. DOI: 10.7619/jcmp.201706016
    [8]DU Yunfeng, ZHAO Dan, YE Xinhua, CHENG Jinluo. Change of bone mineral density in postmenopausal type 2 diabetes mellitus patients with albuminuria and normal renal function[J]. Journal of Clinical Medicine in Practice, 2016, (24): 46-48. DOI: 10.7619/jcmp.201624013
    [9]TAN Haicheng, LIU Chang, LU Cong. Influences of saxagliptin on blood glucose spectrum of the patients with type 2 diabetes mellitus[J]. Journal of Clinical Medicine in Practice, 2013, (21): 128-130. DOI: 10.7619/jcmp.201321038
    [10]LU Xiaoyuan. Effect of ophiopogon-polysaccharide on protection of the kidney in type 2 diabetic rats[J]. Journal of Clinical Medicine in Practice, 2012, (24): 11-14.

  • Cited by

    Periodical cited type(2)

    1. 孙海霞. SGLT-2抑制剂联合常规降糖治疗对2型糖尿病患者血管内皮功能的影响. 吉林医学. 2022(10): 2724-2726 .
    2. 茹松甲，刘晓丽，李胜超. 竹节参总皂苷通过肾素-血管紧张素系统抑制肾癌细胞增殖的研究. 实用临床医药杂志. 2022(21): 34-40 . 本站查看

    Other cited types(0)

Catalog

    Get Citation
    PDF
    XML
    Article views (314) PDF downloads (20) Cited by(2)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    © 2020 《实用临床医药杂志》编辑部

    Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    Supported by: Beijing Renhe Information Technology Co., Ltd.   Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return